We are live on ! Find out more
AZN icon

AstraZeneca

343 hedge funds and large institutions have $6.81B invested in AstraZeneca in 2013 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 140 increasing their positions, 93 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed

181% more call options, than puts

Call options by funds: $140M | Put options by funds: $49.7M

80% more funds holding in top 10

Funds holding in top 10: 5 → 9 (+4)

62% more capital inflows, than outflows

Capital inflows: $965M | Capital outflows: $595M

51% more repeat investments, than reductions

Existing positions increased: 140 | Existing positions reduced: 93

26% more first-time investments, than exits

New positions opened: 43 | Existing positions closed: 34

4% more funds holding

Funds holding: 331 → 343 (+12)

0.6% more ownership

Funds ownership: 9.87% → 10.47% (+0.6%)

Holders
343
Holders Change
+12
Holders Change %
+3.63%
% of All Funds
11.08%
Holding in Top 10
9
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+80%
% of All Funds
0.29%
New
43
Increased
140
Reduced
93
Closed
34
Calls
$140​M
Puts
$49.7​M
Net Calls
+$89.9​M
Net Calls Change
+$15.8​M

AZN Hedge Fund Activity: Q3 2013 in Review

343 of the 3,095 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q3 2013, worth a combined $6.81B — up 16% from $5.85B a quarter earlier.

Buyers outnumbered sellers: 43 funds opened new AZN positions and 34 closed out — a net gain of 9 holders — while 140 added to existing stakes and 93 trimmed.

The largest buyer was Boston Partners, adding an estimated $127M. The largest seller was Arrowstreet Capital, cutting an estimated $151M.

  • 343 institutional investors held AstraZeneca (AZN) as of Q3 2013, up from 331 in Q2 2013.
  • Funds reported $6.81B of AstraZeneca stock for Q3 2013, up 16% quarter-over-quarter.
  • 43 funds opened new AstraZeneca positions in Q3 2013 and 34 closed out, a net change of +9 holders.
  • The largest AstraZeneca buyer in Q3 2013 was Boston Partners, an estimated $127M added.
  • The largest AstraZeneca seller in Q3 2013 was Arrowstreet Capital, an estimated $151M sold.

Based on aggregated 13F filings for Q3 2013.